Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Actavis PLC (ACT), Laboratory Corp. of America Holdings (LH) Among Health Fund Visium’s Top Picks

Page 1 of 2

Visium Asset Management has submitted its 13F filing with the SEC for the reporting period of March 31. The fund was founded in 2005 by Jacob Gottlieb and has a public equity portfolio valued at $6.78 billion as of the reporting period, along with an estimated $14.8 billion in assets under management. Visium invests heavily in healthcare stocks and is often tracked to identify stocks that have great potential in that sector. Unsurprisingly, the kind of growth that the healthcare sector has experienced over the past few years has made it popular with many investors. Over the past three years, the sector has delivered annualized returns of 27.08%, a development that has seen investors of all stripes dive into the sector. Insider Monkey has been keenly following the developments in the sector and has sifted through the 13F filings with the U.S. Securities and Exchange Commission for the aforementioned period. Visium had a high degree of turnover in its public equity portfolio during the past quarter and we’ve taken an in-depth look into some of its top stocks: Actavis PLC (NYSE:ACT), Laboratory Corp. of America Holdings (NYSE:LH), and Perrigo Company PLC Ordinary Shares (NYSE:PRGO).

Jacob Gottlieb - Visium Asset Management

An everyday investor does not have the time or the required skill-set to carry out an in-depth analysis of equities and identify companies with the best future prospects like a fund with the knowledge and resources of Visium can. However, it is also not a good idea to pay the egregiously high fees that investment firms charge for their stock picking expertise. Thus a retail investor is better off to monkey the most popular stock picks among hedge funds by him or herself. But not just any picks mind you. Our research has shown that a portfolio based on hedge funds’ top stock picks (which are invariably comprised entirely of large-cap companies) falls considerably short of a portfolio based on their best small-cap stock picks. The most popular large-cap stocks among hedge funds underperformed the market by an average of seven basis points per month in our back tests whereas the 15 most popular small-cap stock picks among hedge funds outperformed the market by nearly a percentage point per month over the same period between 1999 and 2012. Since officially launching our small-cap strategy in August 2012 it has performed just as predicted, beating the market by over 84 percentage points and returning over 144%, while hedge funds themselves have collectively underperformed the market (read the details here).

Let’s begin with Actavis PLC (NYSE:ACT), which landed on top of the list of the fund’s holdings as of March 31. The firm held a total of 1.46 million shares of the stock valued at $435.24 million, representing an enormous increase over the previous reporting period three months prior when it held only 728,397 shares with a value of $187.50 million. Actavis PLC (NYSE:ACT) has become quite a popular stock with investors, leading not only all other healthcare stocks with 157 of the investors we track having positions in it, but leading all companies, including Apple Inc. (NASDAQ:AAPL), which it knocked off of the top spot. Several brokerages and analysts have weighed in on the stock recently, with Citigroup Inc. giving it a “Focus List” rating (usually a firm’s highest rating) and a price target of $360 while analysts at Leerink Swann reiterated their “Outperform” rating for the stock and have updated their price target on the stock to $352 from $348. The company’s performance in the first quarter was quite impressive, registering a significant increase of 59% in net revenue to $4.2 billion year-over-year. Such results have convinced many investors to bet their money and that of their clients on the stock, including notable investors like Dan Loeb of Third Point and John Paulson of Paulson & Co.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!